Inhibitor Therapeutics, Inc. (INTI)
OTCMKTS
· Delayed Price · Currency is USD
0.0900
+0.0130 (16.88%)
Jun 26, 2026, 4:00 PM EST
Inhibitor Therapeutics Employees
As of December 31, 2025, Inhibitor Therapeutics had 8 total employees, including 2 full-time and 6 part-time employees. The number of employees decreased by 1 or -11.11% compared to the previous year.
Employees
8
Change (1Y)
-1
Growth (1Y)
-11.11%
Revenue / Employee
n/a
Profits / Employee
-$670,783
Market Cap
15.64M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Anebulo Pharmaceuticals | 3 |
| Galera Therapeutics | 3 |
| Zeo ScientifiX | 20 |
| ZIVO Bioscience | 7 |
| Oncotelic Therapeutics | 43 |
| Adaptimmune Therapeutics | 272 |
Inhibitor Therapeutics News
- 3 months ago - Inhibitor Therapeutics Provides Clinical, Formulation and IP Update on Itraconazole Program for Gorlin Syndrome - GlobeNewsWire
- 1 year ago - Complement Inhibitor Therapeutics Pipeline Developments Research Report 2024 - GlobeNewsWire
- 1 year ago - Complement Inhibitors Clinical Trial Pipeline Analysis: 40+ Key Companies Shaping the Future of Complement Inhibitor Therapeutics | DelveInsight - GlobeNewsWire
- 2 years ago - Inhibitor Therapeutics, Inc. Provides Update on its Clinical Development Plan - GlobeNewsWire
- 2 years ago - Introducing Inhibitor Therapeutics, Inc. New Scientific Advisory Board - PRNewsWire
- 2 years ago - Inhibitor Therapeutics, Inc. Exclusive License with Johns Hopkins University - PRNewsWire